Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s10549-007-9546-3.

Title:
Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases | Breast Cancer Research and Treatment
Description:
We have previously demonstrated in a pilot study of 348 invasive breast cancers that mast cell (MC) infiltrates within primary breast cancers are associated with a good prognosis. Our aim was to verify this finding in a larger cohort of invasive breast cancer patients and examine the relationship between the presence of MCs and other clinical and pathological features. Clinically annotated tissue microarrays (TMAs) containing 4,444 cases were constructed and stained with c-Kit (CD-117) using standard immunoperoxidase techniques to identify and quantify MCs. For statistical analysis, we applied a split-sample validation technique. Breast cancer specific survival was analyzed by Kaplan–Meier [KM] method and log rank test was used to compare survival curves. Survival analysis by KM method showed that the presence of stromal MCs was a favourable prognostic factor in the training set (P = 0.001), and the validation set group (P = 0.006). X-tile plot generated to define the optimal number of MCs showed that the presence of any number of stromal MCs predicted good prognosis. Multivariate analysis showed that the MC effect in the training set (Hazard ratio [HR] = 0.804, 95% Confidence interval [CI], 0.653–0.991, P = 0.041) and validation set analysis (HR = 0.846, 95% CI, 0.683–1.049, P = 0.128) was independent of age, tumor grade, tumor size, lymph node, ER and Her2 status. This study concludes that stromal MC infiltration in invasive breast cancer is an independent good prognostic marker and reiterates the critical role of local inflammatory responses in breast cancer progression.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {šŸ“š}

  • Education
  • Science
  • Health & Fitness

Content Management System {šŸ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {šŸ“ˆ}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {šŸ’ø}

We see no obvious way the site makes money.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {šŸ”}

cancer, mcs, breast, tumor, article, cells, analysis, google, scholar, pubmed, cas, mast, cell, patients, set, survival, stromal, invasive, presence, prognostic, training, prognosis, study, cases, validation, number, table, growth, clinical, stained, statistical, size, carcinoma, outcome, lung, tma, data, good, showed, group, status, core, research, access, cohort, ovarian, angiogenesis, cancers, results, factor,

Topics {āœ’ļø}

increased islet/stromal mc-ratio vaccine-mediated antitumor immunity article download pdf x-tile plot generated mast cell-mediated apoptosis outcome-based cut-point optimization split-sample validation technique x-tile analysis results breast-cancer specific survival small-cell lung cancer transforming growth factor-beta tumor necrosis factor-α x-tile program split chymase-positive mast cells related subjects x-tile plot showed anti-tumor effector cells tumor-derived chemo attractants full access inflammatory cell infiltrate stem cell factor platelet-derived growth factor selecting optimal cut-points mc tryptase-mediated fibrosis ca/tma/web/viewer proto-oncogene c-kit stem-cell factors image zooming functionality prognostic model adjuvant her2Ā ihc herceptest scoreĀ =Ā 2 kaplan–meier [km] method hazard ratio [hr]Ā =Ā 0 single oval nucleus high-risk groups based mc-deficient mice compared mast cell chymase vancouver general hospital invasive breast cancer studies showing increase privacy choices/manage cookies type iii receptor mouse mast cells her2+ breast cancer health strategic partnering stromal mast cells median tumor size mast cell populations mast cell secretion male breast cancer invasive breast carcinomas

Schema {šŸ—ŗļø}

WebPage:
      mainEntity:
         headline:Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases
         description:We have previously demonstrated in a pilot study of 348 invasive breast cancers that mast cell (MC) infiltrates within primary breast cancers are associated with a good prognosis. Our aim was to verify this finding in a larger cohort of invasive breast cancer patients and examine the relationship between the presence of MCs and other clinical and pathological features. Clinically annotated tissue microarrays (TMAs) containing 4,444 cases were constructed and stained with c-Kit (CD-117) using standard immunoperoxidase techniques to identify and quantify MCs. For statistical analysis, we applied a split-sample validation technique. Breast cancer specific survival was analyzed by Kaplan–Meier [KM] method and log rank test was used to compare survival curves. Survival analysis by KM method showed that the presence of stromal MCs was a favourable prognostic factor in the training set (PĀ =Ā 0.001), and the validation set group (PĀ =Ā 0.006). X-tile plot generated to define the optimal number of MCs showed that the presence of any number of stromal MCs predicted good prognosis. Multivariate analysis showed that the MC effect in the training set (Hazard ratio [HR]Ā =Ā 0.804, 95% Confidence interval [CI], 0.653–0.991, PĀ =Ā 0.041) and validation set analysis (HRĀ =Ā 0.846, 95% CI, 0.683–1.049, PĀ =Ā 0.128) was independent of age, tumor grade, tumor size, lymph node, ER and Her2 status. This study concludes that stromal MC infiltration in invasive breast cancer is an independent good prognostic marker and reiterates the critical role of local inflammatory responses in breast cancer progression.
         datePublished:2007-03-13T00:00:00Z
         dateModified:2007-03-13T00:00:00Z
         pageStart:249
         pageEnd:257
         license:https://creativecommons.org/licenses/by-nc/2.0/
         sameAs:https://doi.org/10.1007/s10549-007-9546-3
         keywords:
            Breast cancer
            Inflammatory infiltrate
            Mast cells
            Stroma
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-007-9546-3/MediaObjects/10549_2007_9546_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-007-9546-3/MediaObjects/10549_2007_9546_Fig2_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:107
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Ashish B. Rajput
               affiliation:
                     name:Genetic Pathology Evaluation Centre, University of British Columbia
                     address:
                        name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dmitry A. Turbin
               affiliation:
                     name:Genetic Pathology Evaluation Centre, University of British Columbia
                     address:
                        name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Maggie CU Cheang
               affiliation:
                     name:Genetic Pathology Evaluation Centre, University of British Columbia
                     address:
                        name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:David K. Voduc
               affiliation:
                     name:Genetic Pathology Evaluation Centre, University of British Columbia
                     address:
                        name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
                     name:BC Cancer Agency
                     address:
                        name:Department of Radiation Oncology, BC Cancer Agency, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sam Leung
               affiliation:
                     name:Genetic Pathology Evaluation Centre, University of British Columbia
                     address:
                        name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Karen A. Gelmon
               affiliation:
                     name:BC Cancer Agency
                     address:
                        name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:C. Blake Gilks
               affiliation:
                     name:Genetic Pathology Evaluation Centre, University of British Columbia
                     address:
                        name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:David G. Huntsman
               affiliation:
                     name:Genetic Pathology Evaluation Centre, University of British Columbia
                     address:
                        name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
                     name:British Columbia Cancer Agency
                     address:
                        name:British Columbia Cancer Agency, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases
      description:We have previously demonstrated in a pilot study of 348 invasive breast cancers that mast cell (MC) infiltrates within primary breast cancers are associated with a good prognosis. Our aim was to verify this finding in a larger cohort of invasive breast cancer patients and examine the relationship between the presence of MCs and other clinical and pathological features. Clinically annotated tissue microarrays (TMAs) containing 4,444 cases were constructed and stained with c-Kit (CD-117) using standard immunoperoxidase techniques to identify and quantify MCs. For statistical analysis, we applied a split-sample validation technique. Breast cancer specific survival was analyzed by Kaplan–Meier [KM] method and log rank test was used to compare survival curves. Survival analysis by KM method showed that the presence of stromal MCs was a favourable prognostic factor in the training set (PĀ =Ā 0.001), and the validation set group (PĀ =Ā 0.006). X-tile plot generated to define the optimal number of MCs showed that the presence of any number of stromal MCs predicted good prognosis. Multivariate analysis showed that the MC effect in the training set (Hazard ratio [HR]Ā =Ā 0.804, 95% Confidence interval [CI], 0.653–0.991, PĀ =Ā 0.041) and validation set analysis (HRĀ =Ā 0.846, 95% CI, 0.683–1.049, PĀ =Ā 0.128) was independent of age, tumor grade, tumor size, lymph node, ER and Her2 status. This study concludes that stromal MC infiltration in invasive breast cancer is an independent good prognostic marker and reiterates the critical role of local inflammatory responses in breast cancer progression.
      datePublished:2007-03-13T00:00:00Z
      dateModified:2007-03-13T00:00:00Z
      pageStart:249
      pageEnd:257
      license:https://creativecommons.org/licenses/by-nc/2.0/
      sameAs:https://doi.org/10.1007/s10549-007-9546-3
      keywords:
         Breast cancer
         Inflammatory infiltrate
         Mast cells
         Stroma
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-007-9546-3/MediaObjects/10549_2007_9546_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-007-9546-3/MediaObjects/10549_2007_9546_Fig2_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:107
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Ashish B. Rajput
            affiliation:
                  name:Genetic Pathology Evaluation Centre, University of British Columbia
                  address:
                     name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dmitry A. Turbin
            affiliation:
                  name:Genetic Pathology Evaluation Centre, University of British Columbia
                  address:
                     name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Maggie CU Cheang
            affiliation:
                  name:Genetic Pathology Evaluation Centre, University of British Columbia
                  address:
                     name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:David K. Voduc
            affiliation:
                  name:Genetic Pathology Evaluation Centre, University of British Columbia
                  address:
                     name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
                  name:BC Cancer Agency
                  address:
                     name:Department of Radiation Oncology, BC Cancer Agency, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sam Leung
            affiliation:
                  name:Genetic Pathology Evaluation Centre, University of British Columbia
                  address:
                     name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Karen A. Gelmon
            affiliation:
                  name:BC Cancer Agency
                  address:
                     name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:C. Blake Gilks
            affiliation:
                  name:Genetic Pathology Evaluation Centre, University of British Columbia
                  address:
                     name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:David G. Huntsman
            affiliation:
                  name:Genetic Pathology Evaluation Centre, University of British Columbia
                  address:
                     name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
                  name:British Columbia Cancer Agency
                  address:
                     name:British Columbia Cancer Agency, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:107
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Genetic Pathology Evaluation Centre, University of British Columbia
      address:
         name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
         type:PostalAddress
      name:Genetic Pathology Evaluation Centre, University of British Columbia
      address:
         name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
         type:PostalAddress
      name:Genetic Pathology Evaluation Centre, University of British Columbia
      address:
         name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
         type:PostalAddress
      name:Genetic Pathology Evaluation Centre, University of British Columbia
      address:
         name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
         type:PostalAddress
      name:BC Cancer Agency
      address:
         name:Department of Radiation Oncology, BC Cancer Agency, Vancouver, Canada
         type:PostalAddress
      name:Genetic Pathology Evaluation Centre, University of British Columbia
      address:
         name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
         type:PostalAddress
      name:BC Cancer Agency
      address:
         name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
         type:PostalAddress
      name:Genetic Pathology Evaluation Centre, University of British Columbia
      address:
         name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
         type:PostalAddress
      name:Genetic Pathology Evaluation Centre, University of British Columbia
      address:
         name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
         type:PostalAddress
      name:British Columbia Cancer Agency
      address:
         name:British Columbia Cancer Agency, Vancouver, Canada
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Ashish B. Rajput
      affiliation:
            name:Genetic Pathology Evaluation Centre, University of British Columbia
            address:
               name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
               type:PostalAddress
            type:Organization
      name:Dmitry A. Turbin
      affiliation:
            name:Genetic Pathology Evaluation Centre, University of British Columbia
            address:
               name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
               type:PostalAddress
            type:Organization
      name:Maggie CU Cheang
      affiliation:
            name:Genetic Pathology Evaluation Centre, University of British Columbia
            address:
               name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
               type:PostalAddress
            type:Organization
      name:David K. Voduc
      affiliation:
            name:Genetic Pathology Evaluation Centre, University of British Columbia
            address:
               name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
               type:PostalAddress
            type:Organization
            name:BC Cancer Agency
            address:
               name:Department of Radiation Oncology, BC Cancer Agency, Vancouver, Canada
               type:PostalAddress
            type:Organization
      name:Sam Leung
      affiliation:
            name:Genetic Pathology Evaluation Centre, University of British Columbia
            address:
               name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
               type:PostalAddress
            type:Organization
      name:Karen A. Gelmon
      affiliation:
            name:BC Cancer Agency
            address:
               name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
               type:PostalAddress
            type:Organization
      name:C. Blake Gilks
      affiliation:
            name:Genetic Pathology Evaluation Centre, University of British Columbia
            address:
               name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
               type:PostalAddress
            type:Organization
      name:David G. Huntsman
      affiliation:
            name:Genetic Pathology Evaluation Centre, University of British Columbia
            address:
               name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
               type:PostalAddress
            type:Organization
            name:British Columbia Cancer Agency
            address:
               name:British Columbia Cancer Agency, Vancouver, Canada
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
      name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
      name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
      name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
      name:Department of Radiation Oncology, BC Cancer Agency, Vancouver, Canada
      name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
      name:Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
      name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
      name:Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
      name:British Columbia Cancer Agency, Vancouver, Canada

External Links {šŸ”—}(157)

Analytics and Tracking {šŸ“Š}

  • Google Tag Manager

Libraries {šŸ“š}

  • Clipboard.js
  • Prism.js

CDN Services {šŸ“¦}

  • Crossref

5.38s.